OBJECTIVES: To test whether accelerated sarcopenia in older persons with high interleukin (IL)-6 serum levels plays a role in the prospective association between inflammation and disability found in many studies. DESIGN: Cohort study of older women with moderate to severe disability. PARTICIPANTS: Six hundred twenty older women from the Women's Health and Aging Study in whom information on baseline IL-6 serum level was available. MEASUREMENTS: Self-report of functional status, objective measures of walking performance, and knee extensor strength were assessed at baseline and over six semiannual follow-up visits. Potential confounders were baseline age, race, body mass index, smoking, depression, and medical conditions. RESULTS: At baseline, women with high IL-6 were more often disabled and had lower walking speed. After adjusting for confounders, women in the highest IL-6 tertile (IL-6>3.10 pg/mL) were at higher risk of developing incident mobility disability (risk ratio (RR) = 1.50, 95% confidence interval (CI) = 1.01-2.27), disability in activities of daily living (RR = 1.41, 95% CI = 1.01-1.98), and severe limitation in walking (RR = 1.61, 95% CI = 1.09-2.38) and experienced steeper declines in walking speed (P <.001) than women in the lowest IL-6 tertile (IL-6 < or =1.78 pg/mL). Decline in knee extensor strength was also steeper, but differences across IL-6 tertiles were not significant. After adjusting for change over time in knee extensor strength, the association between high IL-6 and accelerated decline of physical function was no longer statistically significant. CONCLUSIONS: Older women with high IL-6 serum levels have a higher risk of developing physical disability and experience a steeper decline in walking ability than those with lower levels, which are partially explained by a parallel decline in muscle strength.
OBJECTIVES: To test whether accelerated sarcopenia in older persons with high interleukin (IL)-6 serum levels plays a role in the prospective association between inflammation and disability found in many studies. DESIGN: Cohort study of older women with moderate to severe disability. PARTICIPANTS: Six hundred twenty older women from the Women's Health and Aging Study in whom information on baseline IL-6 serum level was available. MEASUREMENTS: Self-report of functional status, objective measures of walking performance, and knee extensor strength were assessed at baseline and over six semiannual follow-up visits. Potential confounders were baseline age, race, body mass index, smoking, depression, and medical conditions. RESULTS: At baseline, women with high IL-6 were more often disabled and had lower walking speed. After adjusting for confounders, women in the highest IL-6 tertile (IL-6>3.10 pg/mL) were at higher risk of developing incident mobility disability (risk ratio (RR) = 1.50, 95% confidence interval (CI) = 1.01-2.27), disability in activities of daily living (RR = 1.41, 95% CI = 1.01-1.98), and severe limitation in walking (RR = 1.61, 95% CI = 1.09-2.38) and experienced steeper declines in walking speed (P <.001) than women in the lowest IL-6 tertile (IL-6 < or =1.78 pg/mL). Decline in knee extensor strength was also steeper, but differences across IL-6 tertiles were not significant. After adjusting for change over time in knee extensor strength, the association between high IL-6 and accelerated decline of physical function was no longer statistically significant. CONCLUSIONS: Older women with high IL-6 serum levels have a higher risk of developing physical disability and experience a steeper decline in walking ability than those with lower levels, which are partially explained by a parallel decline in muscle strength.
Authors: J R Ortlepp; J Metrikat; K Vesper; V Mevissen; F Schmitz; M Albrecht; P Maya-Pelzer; P Hanrath; C Weber; K Zerres; R Hoffmann Journal: J Mol Med (Berl) Date: 2003-08-20 Impact factor: 4.599
Authors: Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor Journal: Ageing Res Rev Date: 2015-10-14 Impact factor: 10.895
Authors: Carlo Custodero; Stephen D Anton; Daniel P Beavers; Robert T Mankowski; Stephanie A Lee; Mary M McDermott; Roger A Fielding; Anne B Newman; Russel P Tracy; Stephen B Kritchevsky; Walter T Ambrosius; Marco Pahor; Todd M Manini Journal: Arch Gerontol Geriatr Date: 2020-05-30 Impact factor: 3.250
Authors: Benedetta Bartali; Edward A Frongillo; Martha H Stipanuk; Stefania Bandinelli; Simonetta Salvini; Domenico Palli; Jose A Morais; Stefano Volpato; Jack M Guralnik; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2012-01-27 Impact factor: 5.562
Authors: Candace K McClure; Samar R El Khoudary; Carrie A Karvonen-Gutierrez; Kelly R Ylitalo; Kristin Tomey; Trang VoPham; Barbara Sternfeld; Jane A Cauley; Siobán Harlow Journal: Exp Gerontol Date: 2013-11-07 Impact factor: 4.032
Authors: G Berrut; S Andrieu; I Araujo de Carvalho; J P Baeyens; H Bergman; B Cassim; F Cerreta; M Cesari; H B Cha; L K Chen; A Cherubini; M Y Chou; A J Cruz-Jentoft; L De Decker; P Du; B Forette; F Forette; A Franco; R Guimaraes; L M Guttierrez-Robledo; J Jauregui; V Khavinson; W J Lee; L N Peng; C Perret-Guillaume; M Petrovic; F Retornaz; K Rockwood; L Rodriguez-Manas; C Sieber; G Spatharakis; O Theou; E Topinkova; B Vellas; A Benetos Journal: J Nutr Health Aging Date: 2013 Impact factor: 4.075